Medifast, Inc. Form 8-K Filing Summary

This Form 8-K filing by Medifast, Inc. details significant corporate events that occurred around May 19-26, 2026. The company's stockholders approved an amendment to the Amended and Restated 2012 Share Incentive Plan, increasing the authorized shares by 250,000. Additionally, Nicholas Johnson was appointed as the new Chief Executive Officer, effective June 1, 2026, succeeding Daniel Chard who will transition to non-executive Chairman. Mr. Johnson's compensation package includes a base salary of $600,000, a target bonus of 100% of his base salary, and a Long Term Incentive target at 250% of his base salary. The filing also reports the results of the annual stockholder meeting, including the election of directors, ratification of RSM US LLP as the independent registered public accounting firm, advisory approval of executive compensation, and approval of the Amended 2012 Share Incentive Plan. A press release dated May 26, 2026, confirmed Mr. Johnson's appointment.